PortfoliosLab logo
Akero Therapeutics, Inc. (AKRO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00973Y1082

CUSIP

00973Y108

IPO Date

Jun 20, 2019

Highlights

Market Cap

$3.58B

EPS (TTM)

-$3.75

Gross Profit (TTM)

-$1.00K

EBITDA (TTM)

-$195.02M

Year Range

$17.86 - $58.40

Target Price

$77.64

Short %

8.15%

Short Ratio

5.10

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
AKRO vs. SPY AKRO vs. AVGO
Popular comparisons:

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Akero Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%50.00%100.00%150.00%200.00%December2025FebruaryMarchAprilMay
131.39%
91.73%
AKRO (Akero Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Akero Therapeutics, Inc. (AKRO) returned 52.37% year-to-date (YTD) and 101.67% over the past 12 months.


AKRO

YTD

52.37%

1M

24.53%

6M

21.57%

1Y

101.67%

5Y*

14.05%

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.70%

1M

13.67%

6M

-5.18%

1Y

9.18%

5Y*

14.14%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of AKRO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202594.39%-9.17%-17.59%12.67%-7.06%52.37%
2024-7.45%24.90%-6.41%-21.26%-5.38%24.65%13.94%1.76%5.48%7.46%4.12%-13.33%19.14%
2023-9.67%-8.06%-15.93%16.94%-0.36%4.73%-7.05%14.35%1.91%-76.43%40.44%39.49%-57.39%
2022-17.16%1.20%-19.97%-26.07%-17.64%9.38%8.36%14.75%189.79%24.11%10.03%17.85%159.10%
202114.03%3.33%-4.57%6.17%-15.00%-5.23%-13.58%10.73%-5.86%-3.85%-1.07%-0.52%-18.02%
202011.24%-11.83%-2.62%-3.77%24.61%-1.97%40.89%-7.15%-5.55%-13.77%8.40%-10.35%16.24%
20194.53%26.37%14.50%-17.90%2.02%-15.17%12.72%21.15%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 89, AKRO is among the top 11% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AKRO is 8989
Overall Rank
The Sharpe Ratio Rank of AKRO is 8282
Sharpe Ratio Rank
The Sortino Ratio Rank of AKRO is 9494
Sortino Ratio Rank
The Omega Ratio Rank of AKRO is 8989
Omega Ratio Rank
The Calmar Ratio Rank of AKRO is 8888
Calmar Ratio Rank
The Martin Ratio Rank of AKRO is 8989
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Akero Therapeutics, Inc. (AKRO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current Akero Therapeutics, Inc. Sharpe ratio is 0.92. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Akero Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00December2025FebruaryMarchAprilMay
0.92
0.48
AKRO (Akero Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Akero Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%December2025FebruaryMarchAprilMay
-26.36%
-7.82%
AKRO (Akero Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Akero Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Akero Therapeutics, Inc. was 79.99%, occurring on Oct 27, 2023. Recovery took 318 trading sessions.

The current Akero Therapeutics, Inc. drawdown is 26.36%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-79.99%Jun 14, 202395Oct 27, 2023318Feb 5, 2025413
-79.96%Jul 10, 2020478Jun 1, 202293Oct 13, 2022571
-57.16%Aug 29, 2019139Mar 18, 202073Jul 1, 2020212
-40.86%Feb 6, 202543Apr 8, 2025
-32.68%Jan 3, 202365Apr 5, 202346Jun 12, 2023111

Volatility

Volatility Chart

The current Akero Therapeutics, Inc. volatility is 16.90%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%December2025FebruaryMarchAprilMay
16.90%
11.21%
AKRO (Akero Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Akero Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Akero Therapeutics, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 11.8% positive surprise.


-1.20-1.00-0.80-0.60-0.40AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.99
-1.12
Actual
Estimate

Valuation

The Valuation section provides an overview of how Akero Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AKRO relative to other companies in the Biotechnology industry. Currently, AKRO has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AKRO in comparison with other companies in the Biotechnology industry. Currently, AKRO has a P/B value of 4.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items